[
  {
    "ts": null,
    "headline": "Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights",
    "summary": "Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass",
    "url": "https://finnhub.io/api/news?id=0548e18cba940c526a6e25053b6d2a4f80b3cc8feca9ea40408ec69d6831b6b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564400,
      "headline": "Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights",
      "id": 136246995,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass",
      "url": "https://finnhub.io/api/news?id=0548e18cba940c526a6e25053b6d2a4f80b3cc8feca9ea40408ec69d6831b6b8"
    }
  }
]